Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

Ruben A. Mesa, Srdan Verstovsek

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

In the therapy of the Philadelphia chromosome (Ph)-negative chronic myeloproliferative neoplasms (MPNs)-essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF), hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL), and systemic mast cell disease (SMCD)-we are at an exciting cross-roads where, on the one hand, we are experiencing an explosive increase in our understanding of the pathogenetic mechanisms of these disorders and, on the other hand, we are witnessing rapid evolution of targeted therapies hoping to block these pathogenetic mechanisms. The increased understanding of the role of tyrosine kinases has led to efficacious targeted therapy in CEL and subsets of SMCD. The discovery of the JAK2-V617F and related mutations in ET, PV, and PMF have ushered a wave of investigation into novel tyrosine kinase inhibitors currently being investigated in clinical trials. Current management of each of these conditions requires a thoughtful consideration of prognosis and the risks and benefit of each therapeutic modality.

Original languageEnglish (US)
Title of host publicationLeukemias: Principles and Practice of Therapy
PublisherWiley-Blackwell
Pages362-372
Number of pages11
ISBN (Print)9781405182355
DOIs
StatePublished - Jan 4 2011

Fingerprint

Philadelphia Chromosome
Systemic Mastocytosis
Essential Thrombocythemia
Polycythemia Vera
Primary Myelofibrosis
Protein-Tyrosine Kinases
Neoplasms
Hypereosinophilic Syndrome
Therapeutics
Clinical Trials
Mutation

Keywords

  • Chronic eosinophilic leukemia
  • Essential thrombocythemia
  • Hypereosinophilic syndrome
  • JAK2 mutation
  • Myeloproliferative neoplasms
  • Polycythemia vera
  • Primary myelofibrosis
  • Systemic mast cell disease

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mesa, R. A., & Verstovsek, S. (2011). Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. In Leukemias: Principles and Practice of Therapy (pp. 362-372). Wiley-Blackwell. https://doi.org/10.1002/9781444327359.ch30

Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. / Mesa, Ruben A.; Verstovsek, Srdan.

Leukemias: Principles and Practice of Therapy. Wiley-Blackwell, 2011. p. 362-372.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mesa, RA & Verstovsek, S 2011, Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. in Leukemias: Principles and Practice of Therapy. Wiley-Blackwell, pp. 362-372. https://doi.org/10.1002/9781444327359.ch30
Mesa RA, Verstovsek S. Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. In Leukemias: Principles and Practice of Therapy. Wiley-Blackwell. 2011. p. 362-372 https://doi.org/10.1002/9781444327359.ch30
Mesa, Ruben A. ; Verstovsek, Srdan. / Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Leukemias: Principles and Practice of Therapy. Wiley-Blackwell, 2011. pp. 362-372
@inbook{dc943ae99f3a4662b91d3a9de96d6cc5,
title = "Philadelphia Chromosome-Negative Myeloproliferative Neoplasms",
abstract = "In the therapy of the Philadelphia chromosome (Ph)-negative chronic myeloproliferative neoplasms (MPNs)-essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF), hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL), and systemic mast cell disease (SMCD)-we are at an exciting cross-roads where, on the one hand, we are experiencing an explosive increase in our understanding of the pathogenetic mechanisms of these disorders and, on the other hand, we are witnessing rapid evolution of targeted therapies hoping to block these pathogenetic mechanisms. The increased understanding of the role of tyrosine kinases has led to efficacious targeted therapy in CEL and subsets of SMCD. The discovery of the JAK2-V617F and related mutations in ET, PV, and PMF have ushered a wave of investigation into novel tyrosine kinase inhibitors currently being investigated in clinical trials. Current management of each of these conditions requires a thoughtful consideration of prognosis and the risks and benefit of each therapeutic modality.",
keywords = "Chronic eosinophilic leukemia, Essential thrombocythemia, Hypereosinophilic syndrome, JAK2 mutation, Myeloproliferative neoplasms, Polycythemia vera, Primary myelofibrosis, Systemic mast cell disease",
author = "Mesa, {Ruben A.} and Srdan Verstovsek",
year = "2011",
month = "1",
day = "4",
doi = "10.1002/9781444327359.ch30",
language = "English (US)",
isbn = "9781405182355",
pages = "362--372",
booktitle = "Leukemias: Principles and Practice of Therapy",
publisher = "Wiley-Blackwell",

}

TY - CHAP

T1 - Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

AU - Mesa, Ruben A.

AU - Verstovsek, Srdan

PY - 2011/1/4

Y1 - 2011/1/4

N2 - In the therapy of the Philadelphia chromosome (Ph)-negative chronic myeloproliferative neoplasms (MPNs)-essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF), hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL), and systemic mast cell disease (SMCD)-we are at an exciting cross-roads where, on the one hand, we are experiencing an explosive increase in our understanding of the pathogenetic mechanisms of these disorders and, on the other hand, we are witnessing rapid evolution of targeted therapies hoping to block these pathogenetic mechanisms. The increased understanding of the role of tyrosine kinases has led to efficacious targeted therapy in CEL and subsets of SMCD. The discovery of the JAK2-V617F and related mutations in ET, PV, and PMF have ushered a wave of investigation into novel tyrosine kinase inhibitors currently being investigated in clinical trials. Current management of each of these conditions requires a thoughtful consideration of prognosis and the risks and benefit of each therapeutic modality.

AB - In the therapy of the Philadelphia chromosome (Ph)-negative chronic myeloproliferative neoplasms (MPNs)-essential thrombocythemia (ET), polycythemia vera (PV), primary myelofibrosis (PMF), hypereosinophilic syndrome/chronic eosinophilic leukemia (HES/CEL), and systemic mast cell disease (SMCD)-we are at an exciting cross-roads where, on the one hand, we are experiencing an explosive increase in our understanding of the pathogenetic mechanisms of these disorders and, on the other hand, we are witnessing rapid evolution of targeted therapies hoping to block these pathogenetic mechanisms. The increased understanding of the role of tyrosine kinases has led to efficacious targeted therapy in CEL and subsets of SMCD. The discovery of the JAK2-V617F and related mutations in ET, PV, and PMF have ushered a wave of investigation into novel tyrosine kinase inhibitors currently being investigated in clinical trials. Current management of each of these conditions requires a thoughtful consideration of prognosis and the risks and benefit of each therapeutic modality.

KW - Chronic eosinophilic leukemia

KW - Essential thrombocythemia

KW - Hypereosinophilic syndrome

KW - JAK2 mutation

KW - Myeloproliferative neoplasms

KW - Polycythemia vera

KW - Primary myelofibrosis

KW - Systemic mast cell disease

UR - http://www.scopus.com/inward/record.url?scp=84885491069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885491069&partnerID=8YFLogxK

U2 - 10.1002/9781444327359.ch30

DO - 10.1002/9781444327359.ch30

M3 - Chapter

SN - 9781405182355

SP - 362

EP - 372

BT - Leukemias: Principles and Practice of Therapy

PB - Wiley-Blackwell

ER -